146 related articles for article (PubMed ID: 34157932)
1. Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?
Huan Ng C; Jang-Milligan F; Schultz KR
Pediatr Hematol Oncol; 2021 Aug; 38(5):417-419. PubMed ID: 34157932
[No Abstract] [Full Text] [Related]
2. Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children.
Masetti R; Vendemini F; Quarello P; Girardi K; Prete A; Fagioli F; Pession A; Locatelli F
Pediatr Blood Cancer; 2020 May; 67(5):e28208. PubMed ID: 32065469
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
Li S; Wu R; Wang B; Fu L; Zhu G; Zhou X; Ma J; Zhang L; Qin M
J Pediatr Hematol Oncol; 2019 Jan; 41(1):38-41. PubMed ID: 30080752
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation.
Rivera D; Bastida JM; Lopez-Corral L; Sanchez-Guijo F; Cabrero M; Martin A; Perez E; Lopez-Parra M; Avendaño A; Veiga A; Baile M; Arratibel N; Carrillo J; Vazquez L; Caballero MD; Gonzalez-Porras JR
Bone Marrow Transplant; 2019 May; 54(5):757-761. PubMed ID: 30356164
[No Abstract] [Full Text] [Related]
5. Eltrombopag Add-on Treatment in a Child With Fanconi Aplastic Anemia Awaiting Hematopoietic Stem Cell Transplantation.
Aydin Koker S; Çalişkan Polat A
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e74-e76. PubMed ID: 33560087
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation.
Yuan C; Boyd AM; Nelson J; Patel RD; Varela JC; Goldstein SC; Ahmad S; Zhu X; Mori S
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1320-1324. PubMed ID: 30710685
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag induces major non-toxic hypersiderraemia.
Caillon H; Peterlin P; Chevallier P; Guillaume T; Lebourgeois A; Garnier A; Ropert-Bouchet M; Dejoie T
Br J Haematol; 2019 Jul; 186(2):365-366. PubMed ID: 30873599
[No Abstract] [Full Text] [Related]
8. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.
Fattizzo B; Kulasekararaj AG; Hill A; Benson-Quarm N; Griffin M; Munir T; Arnold L; Riley K; Ireland R; De Lavallade H; Potter V; Consonni D; Hillmen P; Mufti GJ; Barcellini W; Marsh JCW
Haematologica; 2019 Nov; 104(11):e494-e496. PubMed ID: 30890599
[No Abstract] [Full Text] [Related]
9. Management of acquired aplastic anemia in children : A single center experience.
Yazal Erdem A; Arman Bilir Ö; Işık M; Kaçar D; Özbek NY; Yaralı HN
Transfus Apher Sci; 2019 Aug; 58(4):484-490. PubMed ID: 31151809
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.
Hong Y; Li X; Wan B; Li N; Chen Y
Clin Drug Investig; 2019 Feb; 39(2):141-156. PubMed ID: 30406906
[TBL] [Abstract][Full Text] [Related]
11. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
Assi R; Garcia-Manero G; Ravandi F; Borthakur G; Daver NG; Jabbour E; Burger J; Estrov Z; Dinardo CD; Alvarado Y; Hendrickson S; Ferrajoli A; Wierda W; Cortes J; Kantarjian H; Kadia TM
Cancer; 2018 Nov; 124(21):4192-4201. PubMed ID: 30307606
[TBL] [Abstract][Full Text] [Related]
12. Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
Olnes MJ; Scheinberg P; Calvo KR; Desmond R; Tang Y; Dumitriu B; Parikh AR; Soto S; Biancotto A; Feng X; Lozier J; Wu CO; Young NS; Dunbar CE
N Engl J Med; 2012 Jul; 367(1):11-9. PubMed ID: 22762314
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A;
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1825-1831. PubMed ID: 31152794
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
Hwang YY; Gill H; Chan TSY; Leung GMK; Cheung CYM; Kwong YL
Hematology; 2018 Aug; 23(7):399-404. PubMed ID: 29303047
[TBL] [Abstract][Full Text] [Related]
15. An Eltrombopag Red (Plasma) Alert.
Al-Samkari H; Goodarzi K
Acta Haematol; 2021; 144(2):227-228. PubMed ID: 32702690
[TBL] [Abstract][Full Text] [Related]
16. Eltrombopag as initial monotherapy for severe aplastic anemia-a case report.
Rodgers GM; Gilreath JA
Ann Hematol; 2018 Aug; 97(8):1517-1518. PubMed ID: 29560523
[No Abstract] [Full Text] [Related]
17. Iron mobilization in a real life cohort of aplastic anemia patients treated with eltrombopag.
Fattizzo B; Cavallaro F; Milesi G; Barcellini W
Am J Hematol; 2019 Sep; 94(9):E237-E239. PubMed ID: 31172568
[No Abstract] [Full Text] [Related]
18. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.
Desmond R; Townsley DM; Dumitriu B; Olnes MJ; Scheinberg P; Bevans M; Parikh AR; Broder K; Calvo KR; Wu CO; Young NS; Dunbar CE
Blood; 2014 Mar; 123(12):1818-25. PubMed ID: 24345753
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
Fattizzo B; Levati G; Cassin R; Barcellini W
Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag named patient programme for patients with chronic immune thrombocytopenia.
Scully M; Kaczmarski R; Myers B; Collins R; Emohare O; Bolton-Maggs PH
Br J Haematol; 2012 Apr; 157(2):259-60. PubMed ID: 22091659
[No Abstract] [Full Text] [Related]
[Next] [New Search]
